Patrick A. Zweidler ‐McKay
Research Subjects
Research Interests
Patrick A. Zweidler ‐McKay has a total of 479 co-authors. Here are the top co-authors by number of shared publications:
- Marina Konopleva
Albert Einstein College of Medicine
14 shared publications Leonard S. Golfman
12 shared publications- Daniel J. DeAngelo
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
11 shared publications Donna Bucci
11 shared publications- Hagop M. Kantarjian
Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA
11 shared publications Hong Mu
11 shared publications
Latest Publications
- 21 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1243-1246
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)
- 21 March 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (5) , 1243-1246
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)
- 16 May 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (20) , 2053-2058
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.
- 16 May 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (20) , 2053-2058
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.
- Open Access
- 8 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2
- 8 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (3)
Open AccessmiR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 2791
Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model
Disclosures. Poussard:Immunogen Inc.: Research Funding; Stemline Menarini: Research Funding. Boichut:Immunogen Inc.: Research Funding; Stemline Menarini: Resear
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 2791
Open AccessSpatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model
Disclosures. Poussard:Immunogen Inc.: Research Funding; Stemline Menarini: Research Funding. Boichut:Immunogen Inc.: Research Funding; Stemline Menarini: Resear
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
PDF file 118K, This table includes genetic information of the AML patients studied in this manucript
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
PDF file 118K, This table includes genetic information of the AML patients studied in this manucript